Department of Marine Biotechnology and Resources, National Sun Yat-sen University, 70 Lienhai Rd., Kaohsiung 80424, Taiwan.
Department of Medicine, Kaohsiung Armed Forces General Hospital, Kaohsiung 80284, Taiwan.
Int J Mol Sci. 2018 Apr 10;19(4):1137. doi: 10.3390/ijms19041137.
Benign prostate hyperplasia (BPH) is one of the most common urological problems in mid-aged to elderly men. Risk factors of BPH include family history, obesity, type 2 diabetes, and high oxidative stress. The main medication classes for BPH management are alpha blockers and 5α-reductase inhibitors. However, these conventional medicines cause adverse effects. Lycogen™, extracted from WL-APD911, is an anti-oxidant and anti-inflammatory compound. In this study, the effect of Lycogen™ was evaluated in rats with testosterone-induced benign prostate hyperplasia (BPH). Testosterone injections and Lycogen™ administration were carried out for 28 days, and body weights were recorded twice per week. The testosterone injection successfully induced a prostate enlargement. BPH-induced rats treated with different doses of Lycogen™ exhibited a significantly decreased prostate index (PI). Moreover, the Lycogen™ administration recovered the histological abnormalities observed in the prostate of BPH rats. In conclusion, these findings support a dose-dependent preventing effect of Lycogen™ on testosterone-induced BPH in rats and suggest that Lycogen™ may be favorable to the prevention and management of benign prostate hyperplasia.
良性前列腺增生（BPH）是中老年男性最常见的泌尿科问题之一。BPH 的风险因素包括家族史、肥胖、2 型糖尿病和高氧化应激。BPH 管理的主要药物类别是α受体阻滞剂和 5α-还原酶抑制剂。然而，这些传统药物会引起不良反应。Lycogen™是从 WL-APD911 中提取的一种抗氧化和抗炎化合物。在这项研究中，评估了 Lycogen™对睾酮诱导的良性前列腺增生（BPH）大鼠的作用。进行了 28 天的睾酮注射和 Lycogen™给药，每周记录两次体重。睾酮注射成功地诱导了前列腺增大。用不同剂量的 Lycogen™治疗的 BPH 诱导大鼠的前列腺指数（PI）显著降低。此外，Lycogen™给药恢复了 BPH 大鼠前列腺中观察到的组织学异常。总之，这些发现支持 Lycogen™对大鼠睾酮诱导的 BPH 具有剂量依赖性的预防作用，并表明 Lycogen™可能有利于良性前列腺增生的预防和管理。
Zotero 插件
